CD44 targets Na|[plus]||[sol]|H|[plus]| exchanger 1 to mediate MDA-MB-231 cells|[rsquo]| metastasis via the regulation of ERK1|[sol]|2
guangqi chang,jian wang,H Zhang,yi zhang,chunru wang,hongbin xu,yijun lin,lan ma,quhuan li,tao pang
DOI: https://doi.org/10.1038/bjc.2013.809
IF: 9.075
2014-01-01
British Journal of Cancer
Abstract:Breast cancer is the most common malignant cancer in women. In these patients, it is not the primary tumour but its distant metastases that are the predominant causes of treatment failure and patients’ death. Chemotherapy can increase the survival rate of women with breast cancer, but most patients may exhibit resistance to chemotherapy after a while of treatment (Weigelt et al, 2005; Lin et al, 2011; Wang et al, 2011). Metastatic spread and aggressive invasion are obvious characteristics of carcinoma and continue to be the greatest handicap of cancer treatment. It is therefore important to accomplish a better understanding of the molecular mechanisms involved in cancer cell migration. A common feature is that cell migration is a process controlled by both internal and external signals (Dormann and Weijer, 2006). Dysregulation of these signals could underlie the aberrant cell migration observed in cancer cells. CD44 denotes a large family of transmembrane glycoproteins that are expressed in a variety of cells and tissues, including breast tumour cells (Gotte and Yip, 2006). CD44 exhibits extensive molecular heterogeneity and this heterogeneity is derived by alternative splicing of variable exons and post-translational modifications (Bourguignon et al, 2009). CD44 has a critical role in a variety of cellular behaviours, including adhesion, migration, invasion, and survival (Cichy and Pure, 2003). In fact, the high level of CD44 isoforms (particularly CD44s) is considered as an important metastatic tumour marker in a lot of cancers and also implicated in the unfavourable prognosis of multiple carcinomas (Bourguignon, 2001). CD44 is also expressed in tumour stem cells and proposed to be one of the important surface markers that could been used to identify putative cancer stem cells in breast tumours (Shipitsin et al, 2007) as well as in other tumour types, such as prostate (Collins et al, 2005), pancreatic (Li et al, 2007), and head and neck carcinomas (Prince et al, 2007). Recent studies indicate that CD44+ mammary tumour cells are associated with more invasive, proliferative, and angiogenic status, predicting an aggressive tumour cell behaviour (Shipitsin et al, 2007). The Na+/H+ exchanger isoform 1 (NHE1) is an electroneutral plasma membrane transporter that regulates intracellular pH (pHi) (Malo and Fliegel, 2006; Slepkov et al, 2007). Na+/H+ exchanger isoform 1 is ubiquitously expressed in essentially all cell types and multiple roles of NHE1 have been described in recent years. In addition to its primary roles in pHi homeostasis and cell volume regulation, a substantial body of evidence indicates that NHE1 has fundamental roles in control of multiple cellular processes, including cell proliferation, cell death/survival balance, cell mobility, and a wide variety of cell signalling transduction. In cancer cells, NHE1 has been appointed an important role in matrix digestion through matrix metalloproteinases (MMPs), creating an alkaline intracellular and acidic extracellular microenvironment in the front of migrating cells to stimulate directional migration in cancer cells (Stock et al, 2007, 2008; Schneider et al, 2009; Martin et al, 2011). In addition, NHE1 can interact directly with a wide variety of other proteins, as well as with membrane lipids. For instance, in MDA-MB-231 cells, NHE1 was found to be recruited to form a raft-localized complex with CD44 and Rho kinase (Bourguignon et al, 2004; Orlowski and Grinstein, 2004; Boedtkjer et al, 2012). As mentioned above, CD44 can interact with NHE1 leading to breast tumour cell invasion (Bourguignon et al, 2004); however, there was little report about the direct regulating relationship between CD44 and NHE1. Therefore, in this paper, we tried to investigate whether the regulation of NHE1 by CD44 existed in breast cancer, study the potential role of CD44 in metastasis of breast cancer cells, and to evaluate the contribution of the MAPK signalling pathway in this process. We obtained Cariporide from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and MAPK inhibitors PD98059 from Beyotime (Shanghai, China). For western blot analysis, we purchased antibodies against GAPDH, NHE1, anti-phosphospecific p38, ERK1/2, JNK1-2/SAPK, and nonphosphorylated p38, ERK1/2, JNK from Santa Cruz Biotechnology; anti-phosphospecific AKT and nonphosphorylated AKT from Cell Signaling Technology (Boston, MA, USA); anti-CD44 and anti-MMP14 from R&D Systems (Minneapolis, MN, USA); anti-MMP2 and MMP9 from Abcam (Cambridge, MA, USA). The CD44/tet plasmids were gifts from Dr DJJ Waugh (Queen’s University Belfast, Belfast, UK) (Hill et al, 2006). A key feature of cells that have higher CD44 expression is their increased migration and invasion capacity. The results of the cell invasion (Figure 2D) and the wound-healing assay (Figure 2E) showed that the metastatic capacity of MDA-MB-231 cells was inhibited by the downregulation of CD44. The amount of cells that migrated to the lower side of the membrane was significantly reduced and the migration of MDA-MB-231 cells was also prominently decreased after transfected with CD44shRNA (Figure 2F). Degradation of the extracellular matrix (ECM) is a key step of tumour infiltration into normal tissue and beginning metastasis. Matrix metalloproteinases have been shown to contribute to breast cancer metastasis through their ability to degrade the ECM. Matrix metalloproteinase 2, MMP9, and MMP14 are the major proteinases among members of the MMP subfamily involved in pericellular proteolysis associated with cell migration. We next investigated the expressions of MMP2, MMP9, and MMP14 in the CD44-knockdown cell clones. The MMPs’ mRNA expressions decreased significantly as opposed to control as shown by real-time PCR analysis (Figure 2G). Western blotting confirmed the reduced protein expressions of MMPs corresponding to the CD44-silenced cell lines (Figure 2H and Supplementary Figure 3A). These data suggest that the activation of tumour metastasis relies on the expression of CD44 and the downregulated CD44 expression could inhibit the metastatic abilities of MDA-MB-231 cells. To investigate whether the inhibition of NHE1 mediated by CD44 downregulation was the main reason for the decreased metastatic abilities of CD44-silenced MDA-MB-231 cells, so we constructed a NHE1 shRNA to simulate the effect of CD44 on the inhibition of NHE1. Our results demonstrated that the expressions of NHE1 were significantly suppressed in NHE1-silenced MDA-MB-231 cells (Figures 3C and D). Then, we detected the activity of NHE1 in MDA-MB-231 cells after NHE1 interference. Moreover, the NHE1 activity was significantly inhibited when the NHE1 expression was downregulated (Supplementary Figures 2B and D). As our anticipation, this course was strongly together with significantly suppressed invasive and metastatic abilities of MDA-MB-231 cells consistent with the results of CD44-silenced MDA-MB-231 cells (Figures 3E–G). Furthermore, treatment with NHE1 shRNA also downregulated MMP2, MMP9, and MMP14 mRNA expressions (data not shown), and the decreased protein expressions of MMP2, MMP9, and MMP14 were validated by western blotting (Figure 3H). We also used Cariporide, a selective specific inhibitor, to investigate the correlation between CD44 and NHE1. As shown in Figures 3E–G, the invasion and migration of MDA-MB-231 cells markedly decreased after treatment with Cariporide. The mRNA expressions of MMPs were also pronounced suppressed by Cariporide (data not shown) and the protein expressions of MMP2, MMP9, and MMP14 also diminished in a time-dependent manner. The protein expressions of MMP2, MMP9, and MMP14 began to decrease after treatment with Cariporide for 12 h and significantly degraded after incubation for 48 h compared with the internal control (Figure 3I and Supplementary Figure 3B). These results indeed demonstrate that the suppression of CD44 on tumour cell migration and invasion is at least partly via the downregulation of NHE1. The transwell experiment and wound-healing assay were used to study the influence of NHE1 re-expression on the metastasis of tumour cells. As shown in Figures 4C and E, the number of invasive cells in the CD44shRNA/NHE1 group occurred at a higher rate compared with the CD44shRNA groups. In addition, the migration of CD44-silenced MDA-MB-231 cells was also markedly increased when the CD44shRNA-mediated low expression of NHE1 was upregulated (Figures 4D and E). Moreover, we also found that induction of NHE1 led to increase mRNA expressions of MMPs (data not shown), and the increased protein expressions of MMP2, 9, and 14 were finally verified by western blotting (Figure 4F). These results indicate that the invasion and migration of MDA-MB-231 cells were significantly suppressed by CD44shRNA-mediated NHE1 downregulation. Moreover, the invasive and metastatic abilities were clearly recovered after being upregulated the expression of NHE1. In general, these data suggest that CD44 downregulation inhibits NHE1 expression to regulate the metastasis of MDA-MB-231 cells. To further investigate the correlation between CD44 level and NHE1 expression, we also transiently transfected CD44/tet overexpression plasmids into NHE1-silenced MDA-MB-231 cells. The results showed that after transfection with CD44/tet overexpression plasmids, the expressions of CD44 significantly increased and the suppressions of NHE1 expression induced by NHE1 shRNA were neutralized by the upregulation of CD44. The change of NHE1 mRNA expression is up to 2.5-fold multiplication (Supplementary Figures 1A and B). Then, we assessed the impacts of CD44 overexpression on the metastatic capacities of NHE1-silenced MDA-MB-231 cells with transwell experiment and wound-healing assay. The numbers of cells transfected with CD44/tet plasmids evidently increased compared with the control, and the metastatic ability was pronouncedly promoted by CD44/tet plasmids-mediated CD44 upregulation (Supplementary Figures 1C–E). After transfection, the increased mRNA expressions of MMPs were detected by real-time PCR (data not shown) and the inhibitions of MMP2, MMP9, and MMP14 protein expressions induced by NHE1 shRNA were also markedly upregulated by CD44 overexpression (Supplementary Figure 1F). These results clearly indicated that CD44 upregulation elevates the expression of NHE1 and NHE1 participation is indispensable for CD44-mediated invasion and migration of MDA-MB-231 cells. To validate the signaling pathways involved in CD44-mediated cell metastasis, inhibitors for NHE1 or/and MAPK signaling pathway were used to assay their effects on CD44-mediated cell metastasis. As shown in Figures 6F and G, the invasive and metastatic abilities were noticeably reduced pretreatment with Cariporiede or PD98059, a specific inhibitor for ERK1/2. When the two specific inhibitors were simultaneously used in the transwell experiment and wound-healing assay, the migration and invasion of MDA-MB-231 cells reduced much more compared with either inhibitor. And so the ERK1/2 inhibitor PD98059 has a synergistic effect with Cariporide (Figure 6H). Moreover, we also investigated the roles of PD98059 on the expressions of MMPs. As expected, after pretreatment with PD98059 for 6h, MDA-MB-231 cells exhibited significantly reduced MMP2, MMP9, and MMP14 expressions and the protein expressions of MMPs disappeared in a time-dependent manner (Figure 6I and Supplementary Figure 3G). These data suggest that the MAPK signaling pathway was involved in CD44-mediated invasion of MDA-MB-231 cells. Tumour metastasis is the major cause of morbidity in patients diagnosed with solid tumours such as breast cancer (Parker and Sukumar, 2003), ovarian cancer (Bhoola and Hoskins, 2006), and squamous cell carcinomas (Kramer et al, 2005), largely because of the ineffectiveness of current therapies. It is now certain that both oncogenic signaling and some cell surface proteins are directly involved in metastasis of tumour cells and CD44 has been implicated in cancer cell metastasis (Auvinen et al, 2005; Bourguignon, 2008; Yae et al, 2012). A wide range of evidence indicates that the expression of CD44 in malignant tumour is higher than that in benign tumour (Shipitsin et al, 2007). Consistent with the reports, we detected that CD44 were highly expressed in MDA-MB-231 cells but lower in MCF-7 cells. The results imply that these must be a functional link between CD44 and tumour metastasis. To ensure the CD44-mediated effects on metastasis, CD44 was silenced in MDA-MB-231 cells and our results indicate that the downregulated expression of CD44 indeed markedly decreased metastasis of MDA-MB-231 cells. Pham et al (2011) found that the expression of CD44 was important for breast cancer stem cells and our findings are consistent with the above report and suggest that CD44 is considered as a promising target for anticancer treatment, especially to breast cancer. Then, the CD44 expression was upregulated in MCF-7 cells and our findings indicate that the metastatic capacities of MCF-7 cells were clearly activated by CD44 upregulation. The activity of the major pH-regulating transporters NHE1 and the pHi values of normal and tumour cells are different. Na+/H+ exchanger isoform 1 is almost quiescent in normal cells, but in tumour cells, the hyper-activated NHE1 results in an increase in pHi and acidification of the extracellular space. Owing to the positive-feedback vicious cycle between the extracellular microenvironment and tumour cells, an ever-higher reversed pH gradient is achieved as the disease progresses. However, little is known about the signal-transduction systems that regulate the NHE1 activity and that are associated with tumour cell invasiveness (Stuwe et al, 2007; Yang et al, 2010). Extracellular acidification has been correlated with the metastatic capacity of tumour cells by promoting neo-angiogenesis, anchorage-independent growth, and invasiveness (Pedersen et al, 2007). Recent studies have demonstrated that NHE1 activity and expression increased in a variety of tumour cells including breast cancer cells (Cardone et al, 2005; Lin et al, 2011). Bourguignon et al (2004) found that in breast cancer cells the interaction of CD44 and NHE1 with hyaluronidase-2 in lipid rafts could induce matrix degradation and breast tumour cell invasion. However, there is no report to date indicating the direct regulating relationship between CD44 and NHE1, even the role of NHE1 in CD44-driven metastasis. Our findings demonstrated that downregulation of CD44 inhibited the expression and activity of NHE1, but whether NHE1 is indispensable in CD44-mediated MDA-MB-231 cells invasion is unknown. We used NHE1 shRNA and Cariporide to simulate the inhibition effect of CD44 on NHE1. The results indicate that both NHE1 shRNA and Cariporide significantly decreased the metastasis of MDA-MB-231 cells. To further clarify whether NHE1 participates in CD44-mediated MDA-MB-231 cells invasion, we overexpressed CD44 in NHE1-silenced MDA-MB-231 cells. Our findings demonstrate that CD44 upregulation restores the invasion and migration of NHE-silenced MDA-MB-231 cells, and the expressions of NHE1 are markedly increased. We also overexpressed CD44 expression in MCF-7 cells and found that both NHE expression and the metastasis of MCF-7 cells were elevated by CD44 overexpression. When we treated CD44-overexpressed MCF-7 cells with Cariporide, the elevated metastasis of MCF-7 cells mediated by CD44 overexpression was downregulated by NHE inhibition. These data indicate that the inhibition of CD44 can decrease NHE1 expression and CD44 upregulation can increase NHE1 expression. And so CD44 mediates the metastasis of breast cancer cells mainly through regulating NHE1 expression. Tumour progression involves a series of different biological obstacles that tumour cells must overcome to form a metastatic tumour. Moreover, it is now clear that MMPs contribute to all stages of tumour progression (Wagenaar-Miller et al, 2004). Matrix metalloproteinases are a family of zinc-required matrix-degrading proteases that have an important role in tumour cell metastasis (Littlepage et al, 2010). To date, Twenty-five members of this family have been described, and their products can be sub-grouped into the soluble-type MMPs and the membrane-type MMPs (Kessenbrock et al, 2010). An increasing body of evidence has verified that the MMPs’ expressions levels are closely associated with the malignancy of tumours (Doi et al, 2011). Recent studies have shown that hyaluronic acid strongly activates MMP2 secretion due to CD44 expression (Zhang et al, 2002). Moreover, it has been testified that the interaction of MMP9 and CD44 is crucial to the migration of fibrosarcoma cells (Dufour et al, 2010). Thus, it appears that CD44 and MMPs are all involved in the initiation of tumour metastasis. In the current studies, we showed that CD44 downregulation resulted in decreased MMPs’ expressions in MDA-MB-231 cells. These results suggest that CD44 can regulate the MMPs’ expressions, but whether MMP is required in CD44-mediated tumour cells metastasis is unknown. For this reason, we overexpressed CD44 in MCF-7 cells and found a significant increase in MCF-7 cells metastasis. However, some reports found that MT-MMPs could cleave CD44 and promoted cell metastasis in some tumour cell lines such as glioblastoma cell lines, pancreatic cancer cell lines, and lung cancer cell lines (Okamoto et al, 1999; Kajita et al, 2001). Moreover, these plausible different results may be from the different tumour cell lines and Okamoto et al (2002) also found that only 67% of breast carcinomas had CD44 cleavage. However, whether there is a loop regulating relationship between CD44 and MMPs needs to be further investigated. A growing body of literatures implicate that CD44 regulates the activities of ERK1/2, PI3K, and NF- kappa B, and so on, yet the effects of CD44 on signaling pathway activities are highly context- and cell type-specific. For example, Bourguignon et al (2009) reported that the p300 signaling pathways activated by HA/CD44 participated in the production of MDR1 in breast tumour cells. Furthermore, Abdraboh et al (2011) found that CD44 induced the expression of survivin leading to breast tumour invasion through the PI3K signaling pathway. To gain more mechanistic insight into how CD44 mediates MDA-MB-231 cells metastasis, we inspected the activities of AKT, and MAPK subfamilies. Our results indicate that downregulation of CD44 obviously decreased the phosphorylation level of ERK1/2, but AKT, p38 MAPK, and JNK activities were not influenced. Furthermore, we overexpressed CD44 in MCF-7 cells and found the phosphorylation of ERK1/2 was markedly increased by upregulation of CD44. Moreover, these results were also testified in NHE1-knockdown MDA-MB-231 cells. In addition, the invasion and migration of MDA-MB-231 cells treated with PD98059 were steeply depressed, and the inhibition was greater when pretreated with Cariporide. Therefore, the inhibitor of ERK1/2 has an additional inhibition effect with Cariporide. These results reveal that ERK1/2 but not AKT, p38 MAPK, and JNK contribute to CD44-mediated MDA-MB-231 cells metastasis. To further clarify whether the effect of CD44 on MMPs’ expressions depend on ERK1/2 signaling pathways, we treated MDA-MB-231 cells with ERK1/2 inhibitor and found the expressions of MMPs were downregulated in a time-dependent manner. Considering these data, we conclude that CD44 targets NHE1 to regulate the expressions of MMPs through ERK1/2 signaling pathways in CD44-mediated tumour cell metastasis. Taken together, the regulatory mechanisms of CD44 on NHE1 can be summarised as follows (Supplementary Figure 4). According to the previous studies, the EGFR may localise in the membrane of tumour cells with NHE1 and CD44 (Chiang et al, 2008; Midgley et al, 2013). Moreover, in our study we first investigate the direct regulating correlation between CD44 and NHE1 in MDA-MB-231 cells. The downregulation of CD44 can inhibit NHE1 abundance and activity, which likely in turn suppresses the motility of breast cancer cells. The inhibition of NHE1 almost abolishes CD44-stimulated breast cancer cells’ motility. Moreover, when the activity of NHE1 was inhibited, the expressions of p-ERK1/2 and MMPs were suppressed. Furthermore, the expressions of MMPs were also regulated by p-ERK1/2. Therefore, in the process of CD44-mediated MDA-MB-231 metastasis, NHE1 is a target of CD44 to regulate the expressions of MMPs through the ERK1/2 signaling pathway. Our findings provide a theoretical basis that simultaneously targeting to CD44 and NHE1 may be novel therapeutic strategies for treating breast cancer. The authors declare no conflict of interest. This work was supported by a grant from the National Natural Science General Program Foundation of China (No. 81170510) and Major Program Foundation of China (No. 81090410). We also thank Dr DJJ Waugh at the Centre for Cancer Research and Cell Biology, Queens University Belfast, University Floor, Belfast City Hospital, Northern Ireland for providing the CD44/tet plasmids. Supplementary Information accompanies this paper on British Journal of Cancer website